Organizers: Neil Strotman, Director, Catalysis and LCS, Merck; Brad Gates, Principal Research Scientist I, AbbVie
Earth-abundant metal catalysis is touted for its inherent sustainability, and the advantages of low toxicity and minimal environmental impact versus heavy metal catalysis. What is often overlooked is the diversity of transformations which can be affected by earth-abundant metals, beyond those of their precious metal counterparts. Earth-abundant metals, by virtue of their placement on the periodic table, have access to more oxidation states, and can often participate in one electron chemistry. This opportunity for more numerous catalytically relevant oxidation states for a given metal allows for greater variety in chemical transformations. This highly active field of research continues to grow and evolve as new catalyst systems succeed in not only supplanting less abundant metals with greener alternatives, but in offering novel reactivity giving rise to greater chemical space.
Organizers: Amy Dounay, Colorado College; Jozef Stec, Marshall B. Ketchum University
Innovative green chemistry approaches have been applied toward all stages of drug discovery research, from the initial medicinal chemistry design to the discovery and manufacturing-scale production of new medicines. Many contemporary efforts in manufacturing of pharmaceuticals aim to be sustainable, environmentally responsible, and fiscally sound, which altogether result in an increased global access to essential medicines and it closely aligns with the WHO’s vision to live in a disease-free world. This symposium is aimed at providing diverse chemists across academe and industry with highly practical knowledge and accessible green chemistry tools to implement into drug discovery and development process at every level in every place. The central theme of this symposium will be showcasing recent developments and innovations in designing green approaches to synthetic medicinal chemistry and manufacturing processes to address current and future global challenges in drug discovery and development.
Organizers: Megan Shaw, Sr. Scientist, Merck; Kevin Maloney, Director, Merck
Traditionally, chemists have relied on the use of organic solvents as the primary reaction medium for both academic research and the development of industrial processes. While offering desirable attributes with respect to solubilizing organic compounds and promoting reactivity, organic solvents contribute heavily to overall waste generation, have negative implications for the environment and often derive from finite resources. This session will outline the largely untapped potential of conducting chemistry in water by demonstrating that, not only does water provide a green and sustainable alternative to organic solvents, it can offer distinct advantages with respect to reactivity, cost efficiency and waste generation. Successful strategies which overcome the commonly perceived challenges of low solubility and stability of organic/organometallic molecules in water will be discussed and the exciting opportunities arising from the use of enzymes, catalysts ideally suited to an aqueous environment, in organic synthesis will be highlighted.
Organizer: Joseph Sabol, Principal-Consultant, Chemical Consultant
More than 35 Gt of carbon dioxide (10 Gt as carbon) from industrial processes is produced each year, with about half accumulating into the oceans and on land and about half retained in the atmosphere. Atmospheric carbon dioxide has risen from 280 ppm in 1800 to 410 ppm in 2019, with the majority coming from human-derived activity. Adverse consequences from lowering the pH of the oceans and warming the atmosphere from trapping infrared radiation are well documented and unabated release of carbon dioxide will exacerbate existing environmental concerns. Unless a significant reduction in carbon dioxide emission is met with world-wide acceptance, rising concentrations, including an increasing rate of emission, are inevitable. Proposals to treat carbon dioxide as waste and inject into deep wells are met with skepticism and daunting engineering challenges. Planting massive forests will take decades to make a significant impact in. In the spirit of “systems-inspired design” this symposium proposes to address viable industrial processes that can re-use “waste” carbon dioxide as a raw material into process streams. Speakers are sought to present concepts and practices that demonstrate viable scale-up processes that use carbon dioxide as a raw material and eliminate waste discharge into the atmosphere.
Organizers: Jason Stevens, Senior Research Investigator II, Bristol-Myers Squibb; Jared Piper, Pfizer
Identification of expedient and resource-efficient synthetic routes and the implementation of an optimal combination of catalysts and reagents for an organic transformation are key endeavors that exemplify green chemistry in practice. This session will focus on in silico techniques that look to deliver synthetic efficiency, atom economy and minimize waste production. Artificial intelligence (AI), machine learning (ML), and predictive analytics (PA) that harness powerful algorithms to improve synthetic routes or chemical reactions from first principles will comprise the majority of the session, as well as what is needed to get started on this important and growing topic in the chemical sciences.
Organizer: David Leahy, Associate Director, Process Chemistry Development, Takeda Pharmaceuticals
The development of new synthetic methodologies and strategies has been the cornerstone upon which sustainable industrial processes are built. The pure research advances arising from academia fuel the world’s industrial innovation, while also training the scientific leaders of tomorrow. This special session highlights the research of graduate students and post-doctoral fellows across the broader organic chemistry community which has the potential to impact sustainable industrial chemistry.
**Students accepted to speak in this session will receive a travel award, provided by the ACS GCI Pharmaceutical Roundtable.**
Get the details of the Travel Awards here.
Organizer: Michael Kopach, Senior Research Advisor, Eli Lilly
Peptides have gained increased interest as therapeutics over the past few decades, largely due to their advantageous properties including high specificity and affinity, as well as superior safety and tolerance. These properties make peptide drugs more desirable than small molecule drugs in select disease classes including cancer, diabetes, degenerative and infectious diseases. Currently, there are over 60 FDA approved peptide drugs on the market and over 600 either in clinical trials or pre-clinical development. Peptide-based therapeutic agents have the potential to replace many existing small molecule-based therapies in the near future. Likewise great strides have been made in oligonucleotide therapies and delivery technologies over the past five years.
Compared to the synthetic processes for small molecule drugs, the environmental impact of this technology has not garnered much attention, in part because the high potency of peptide and oligonucleotide drugs has rendered supply needs significantly lower than traditional small molecule drugs. However, market forecasts indicate potential for a significant increase in high volume peptide and oligonucleotide processes. Recent investigations have revealed that, on average, producing 1 kg of peptide or oligonucleotide products require over 5 to 15 metric tons of solvent, significantly higher than all types of synthetic small molecule. In addition, the current state of the art in peptide and oligonucleotide syntheses utilize primarily legacy technologies, with little focus on green chemistry and engineering with multiple usages of highly hazardous reagents and solvents. Contributing to the poor environmental profile for peptide and oligonucleotide products is the ubiquitous use of chromatography. Recognizing these unmet environmental needs the ACS Pharmaceutical Roundtable recently founded a team focused on improving sustainability practices in peptide and oligonucleotide syntheses. The groups initial contribution is focused on stimulating innovations in peptide syntheses (J. Org. Chem., 2019, 84 (8), pp 4615–4628). This session will explore how improved synthetic methodologies, safer coupling reagents, solvent selection, and minimization of chromatography play a vital role in improving the sustainability both peptide and oligonucleotide syntheses.
Organizers: Cindy Hong, Sr. Scientist, Merck; Kevin Maloney
The facile access to engineered enzymes has led to the widespread adoption of biocatalysis in complex molecule synthesis in both academic as well as industrial laboratories. This session will attempt to highlight the mostly untapped potential of bio-catalysis and protein engineering in developing new synthetic methodologies that unlock new chemical space and are green and sustainable. In addition, the session will highlight the chemistry and engineering challenges associated with developing biocatalytic transformations, and how computational chemistry along with a detailed mechanistic understanding can aid in developing robust processes.